Prostate Cell News Volume 2.42 | Nov 18 2011

SLUG Promotes Prostate Cancer Cell Migration and Invasion via CXCR4/CXCL12 Axis
Researchers provide the first compelling evidence that upregulation of autocrine CXCL12 is a major mechanism underlying SLUG-mediated migration and invasion of prostate cancer cells. [Mol Cancer] Abstract

Role and Expression of FRS2 and FRS3 in Prostate Cancer
Here researchers investigated FGF receptor substrates (FRS2 and FRS3) as a means of disrupting global FGF signaling in prostate cancer. [BMC Cancer] Abstract

CLINICAL RESEARCH

Denosumab and Bone-Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer: Results of a Phase III, Randomized, Placebo-Controlled Trial
Researchers assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer. [Lancet] Abstract

Beta-Carotene Antioxidant Use during Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study
Researchers performed a prospective study nested within the Physicians’ Health Study randomized trial to determine if supplemental antioxidant use during radiation therapy for prostate cancer is associated with an increased risk of prostate cancer death or metastases. [Int J Radiat Oncol Biol Phys] Abstract

High Dose Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
Researchers evaluated their retrospective, single institution experience with high dose rate brachytherapy as monotherapy for intermediate risk prostate cancer. [J Urol] Abstract

Evaluation of Glutathione-S-Transferase P1 and Adenomatous Polyposis Coli Methylation as Indicators for Repeat Biopsy in a High-Risk Cohort of Men with Negative Initial Prostate Biopsies
The objective of this study was to evaluate the performance of DNA methylation biomarkers in the setting of repeat biopsy in men with an initially negative prostate biopsy but a high index of suspicion for missed prostate cancer. [BJU Int] Abstract | Press Release

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72^nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72^nd Scientific Sessions, Philadelphia] Press Release

GSU Researcher Receives Grant to Explore Sweeter, Greener Ways to Naturally Fight Cancer
The American Cancer Society has awarded a $720,000 grant to a Georgia State University (GSU) scientist to explore the cancer preventing benefits of sweet potato greens in prostate cancer. [Georgia State University] Press Release

Oklahoma’s Tobacco Settlement Endowment Fund to Support Cancer Research at Stephenson Cancer Center and Affiliated Research Institutions
The Peggy and Charles Stephenson Cancer Center at the University of Oklahoma Health Sciences Center has received the largest grant in its history – a five-year, $30 million grant – from the Oklahoma Tobacco Settlement Endowment Trust to help translate promising research into new and more effective cancer treatments and diagnostic tools. [The University of Oklahoma Health Sciences Center] Press Release

Cancer Immunotherapy Consortium Appoints New Leadership
The Cancer Research Institute (CRI), Inc. announced that James P. Allison, Ph.D., chair of the immunology program at Memorial Sloan-Kettering Cancer Center, and Axel Hoos, M.D., Ph.D., medical lead in immunology/oncology at Bristol-Myers Squibb, have been named directors of the CRI Cancer Immunotherapy Consortium. [Cancer Research Institute] Press Release

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.